Immune Regulation News Volume 2.08 | Mar 5 2010

    By
    Justin.choi
    -
    0
    83

    Immune Regulation News 2.08, March 5, 2010.
    In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  EventsSubscribe  |  Unsubscribe


    TOP STORY

    Uncovering the In Vivo Role of the Protein DO
    Using a mouse model of type 1 diabetes, scientists have clearly defined the in vivo biological role of the immune system protein DO, something that had not been well characterized before. [Press release from ScienceDaily discussing online prepublication in Journal of Clinical Investigation]

    Request A Poster 
    Isolate Untouched Cells for
    Antigen Processing and Presentation
    with EasySep®
    		 
     
    REQUEST A POSTERSTEMCELL Technologies Inc
    		 

    SPECIAL FEATURE

    Video – EasySep® – Powerful Immunomagnetic Isolation of Virtually Any Cell Type

    SCIENCE NEWS

    New University of Colorado-Boulder Paper Shows Novel Way to Study Human Inflammatory Disease
    A new study shows mice infected with the bacteria salmonella develop clinical signs consistent with a deadly and poorly understood human inflammatory disease, a finding that may lead to new therapies. [University of Colorado at Boulder Press Release]

    Scientists Discover Cause of Destructive Inflammations
    The signaling molecule CD95L, known as “death messenger,” causes an inflammatory process in injured tissue after spinal cord injuries and prevents its healing. [Press release from EurekAlert! discussing online prepublication in Immunity]

    NegSelRosetteSep_645x110_v01

    CURRENT PUBLICATIONS

    An Slfn2 Mutation Causes Lymphoid and Myeloid Immunodeficiency Due to Loss of Immune Cell Quiescence
    These findings identify a physiological role for Schlafen-2 (Slfn2) in the defense against pathogens through the regulation of quiescence in T cells and monocytes. [Nat Immunol]

    Unique Autoreactive T Cells Recognize Insulin Peptides Generated Within the Islets of Langerhans in Autoimmune Diabetes
    A set of autoreactive CD4+ T cells specific for an insulin peptide, with the noteworthy feature of not recognizing the insulin protein when processed by antigen-presenting cells, escaped thymic control, participated in diabetes and caused disease. [Nat Immunol]

    Alternative Cross-Priming Through CCL17-CCR4-Mediated Attraction of Cytotoxic T Cells Toward Natural Killer T Cell-Licensed Dendritic Cells
    Here researchers demonstrate an alternative mechanism for cognate licensing by natural killer T cells recognizing microbial or synthetic glycolipid antigens. [Nat Immunol]

    Targeted Regulation of Self-Peptide Presentation Prevents Type I Diabetes in Mice Without Disrupting General Immunocompetence
    These studies show that DO expression can shape the overall MHCII self-peptide repertoire to promote T cell tolerance. [J Clin Invest ]

    CD73 on Tumor Cells Impairs Antitumor T Cell Responses: A Novel Mechanism of Tumor-Induced Immune Suppression
    These findings identify a potential mechanism for CD73-mediated tumor immune evasion and point to a novel cancer immunotherapy strategy by targeting the enzymatic activity of tumor CD73. [Cancer Res]

    Activation of Tolerogenic Dendritic Cells in the Tumor Draining Lymph Nodes by CD8+ T Cells Engineered to Express CD40 Ligand
    In this study, researchers investigated the effects of local delivery of CD40L by tumor-reactive CD8+ T cells on dendritic cell activation and antitumor T cell responses in the TRAMP model. [J Immunol]

    Mast Cells Express IL-17A in Rheumatoid Arthritis Synovium
    These data are consistent with a crucial role for IL-17A in rheumatoid arthritis pathogenesis but suggest that in addition to T cells innate immune pathways particularly mediated via mast cells may be an important component of the effector IL-17A response. [J Immunol]

    Effective Immunotherapy of Weakly Immunogenic Solid Tumours Using a Combined Immunogene Therapy and Regulatory T Cell Inactivation
    Researchers report an effective immune-based treatment of weakly immunogenic, growing solid tumours using a locally delivered immunogene therapy to promote development of immune effector responses in the tumour microenvironment and a systemic based T regulatory cell inactivation strategy to potentiate these responses by elimination of tolerogenic or immune suppressor influences. [Cancer Gene Ther]

    INDUSTRY NEWS

    United Kingdom Cost Agency Recommends Roche Arthritis Drug
    Roche’s top-selling drug MabThera has been recommended by Britain’s health cost agency for treating some patients with rheumatoid arthritis, in combination with the older drug methotrexate. [Reuters]

    Human Genome Sciences Rises After 4Q Report
    The Rockville, Md., company posted a quarterly loss of 6 cents per share on revenue of $53 million. Analysts polled by Thomson Reuters expected a loss of 10 cents per share on revenue of $50.7 million. [BusinessWeek]

    Comprehensive Report on the Global State of Autoimmune Diseases Released for National Autoimmune Disease Awareness Month
    A groundbreaking new report from the American Autoimmune Related Diseases Association, examining the current state of autoimmune disease and its economic and social impact globally and in the U.S., was released at the National Autoimmune Diseases Summit: The Global State of Autoimmunity Today, held to kick-off National Autoimmune Disease Awareness Month. [PR Newswire]

    La Jolla Pharmaceutical Announces Delisting from NASDAQ and Failure to Get Stockholder Vote for Merger
    La Jolla Pharmaceutical Company announced that it received notification from the Nasdaq Hearings Panel that the Panel has determined to deny the Company’s request for continued listing on The Nasdaq Stock Market and that trading of the Company’s common stock will be suspended effective at the open of business on Thursday, March 4, 2010. [La Jolla Pharmaceutical Press Release]

    POLICY NEWS

    Study Finds Stem Cell Research in the State of Maryland Supports More than 500 Local Jobs and Facilitates $71.3 Million in Business Sales Annually
    A recent third party economic development impact study conducted by Sage Policy Group, Inc., entitled “Economic Benefits of Maryland’s Stem Cell Program Already Apparent,” found that Maryland’s Stem Cell Research Fund supports 514 local jobs, with an average salary of $64,000, and facilitates $71.3 million in business sales in the state. [Maryland Stem Cell Research Fund, United States]

    Idaho Senate Votes 21-13 for ‘Conscience’ Bill
    After a long and emotional debate, Senators voted 21-13 to allow pharmacists, nurses and other health-care workers to opt out of providing assistance for abortions, stem cell therapy, emergency contraception or end-of-life care, if they first tell their employers the procedures violate their conscience. [Idaho Senate, United States]

    Indian Council of Medical Research to Set Up Apex Committee to Regulate Stem Cell Research
    Indian Council of Medical Research said recently it would soon set up a body to regulate the scientific community on the crucial health research of stem cell therapy. [Indian Council of Medical Research, India]

    Suit Possible Over Baby DNA Sent to Military Lab for National Database
    An Austin lawyer threatened to pursue a new federal lawsuit after learning that some newborn blood samples in Texas went to the U.S. military for potential use in a database for law enforcement purposes. [The Statesman, United States]

    2010 Biological License Application Approvals [Food and Drug Administration, United States]

    2009 Biological New Drug Application (NDA) and Abbreviated New Drug Application (ANDA) Approvals [Food and Drug Administration, United States]

    MHRA Seeks Views On Making Information About Medicines Available Online – Your Last Chance to Input [Medicines and Healthcare Products Regulatory Agency, United Kingdom]

    Information Sent to Healthcare Professionals in February 2010 About the Safety of Medicines [Medicines and Healthcare Products Regulatory Agency, United Kingdom]

    Prescription Medicines Business Process Reform Project: Improved Access to Information (Updated) [Therapeutic Goods Administration, Australia]

    EVENTS

    World Immune Regulation Meeting (WIRM) – IV
    March 29-April 01, 2010
    Davos, Switzerland


    American Association for Cancer Research (AACR) 101st Annual Meeting 2010
    April 17-21, 2010
    Washington, DC, United States


    23rd Annual Canadian Society for Immunology (CSI) Conference
    April 23-26, 2010
    Niagara Falls, Canada


    97th Annual Meeting of the American Association of Immunologists (AAI)
    May 7-11, 2010
    Baltimore, United States


    29th Congress of the European Academy of Allergy and Clinical Immunology (EAACI)
    June 5-9, 2010
    London, United Kingdom


    Keystone Symposia: Innate Immunity – Mechanisms Linking with Adaptive Immunity (D3)
    June 7-12, 2010
    Dublin, Ireland


    Federation of Clinical Immunology Societies (FOCIS) 2010
    June 24-27, 2010
    Boston, United States

    Frontiers in Immunology Research (FIRN) 2010 International Conference
    July 22-26, 2010
    Athens, Greece


    14th International Congress of Immunology
    August 22-27, 2010
    Kobe, Japan


    Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

     

    JOB OPPORTUNITIES

    Manufacturing Sciences Technologist – Cell Culture (STEMCELL Technologies)


    Research & Development Technologist (STEMCELL Technologies)


    Recruit Top Talent
    Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.

    Visit     here to post your career opportunities.

     

     


    Have we missed an important article or publication in Immune Regulation News? Click here to submit!

     

    Learn more about Immune Regulation News: Archives  |  Events  |  Subscribe  |  Contact Us